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Background: Laparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoscopic sleeve gastrectomy (LSG)
are associated with glucose metabolism improvement although data on insulin resistance remission
rates after these procedures are lacking.
Aims: Primary aimwas to compare insulin resistance remission rates achieved after LRYGB and LSG, using
population-speciﬁc HOMA-IR cut-off points. Secondary objectives were to analyze factors associated
with type 2 diabetes mellitus (T2DM) complete remission according to the new American Diabetes
Association criteria and to examine changes in HOMA-B during follow-up.
Methods: Non-randomized, prospective cohort study of patients undergoing LRYGB or LSG with a min-
imal follow-up of 24 months. Patients on insulin therapy were excluded.
Results: At baseline, 56 (48.7%) of the 115 LRYGB group and 48 (61.5%) of the 78 LSG group had insulin
resistance, and 29 (25.2%) and 20 (25.6%) T2DM, respectively. No differences were detected in insulin
resistance remission rate (92.9% LRYGB and 87.5% LSG, p ¼ 0.355) nor in T2DM complete remission at 2
years (62.1 vs 60% respectively, p ¼ 0.992). Factors independently associated with T2DM complete
remission were diabetes treatment and a greater decrease in 3-month HOMA-IR index. The HOMA-B
index showed a progressive decline during follow-up.
Conclusion: Both surgical techniques are equally effective in achieving insulin resistance normalization in
the majority of severely obese patients. Three-month HOMA-IR reduction after surgery was the main
predictor of T2DM complete remission.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
In addition to weight loss, some bariatric procedures appear to
have independent metabolic beneﬁts associated with incretin ef-
fects and possibly other hormonal and neural mechanisms.1 In this
respect, laparoscopic sleeve gastrectomy (LSG) has yielded better
results than other restrictive techniques in terms of weight loss and
improved glucose metabolism2 but similar or slightly inferior
outcomes when compared with hybrid techniques such as lapa-
roscopic Roux-en-Y gastric bypass (LRYGB).3e5 Although theent of Endocrinology, Passeig
þ34 932483902; fax: þ34
aiges).
ciates Ltd. Published by Elsevier Ltbeneﬁcial effects of bariatric surgery on glucose metabolism are
known, data on insulin resistance remission rates after surgery are
lacking. In clinical practice, insulin resistance and beta-cell function
have been assessed over the last 20 years by the homeostatic model
assessment (HOMA-IR and HOMA-B, respectively).6 Despite a good
correlation with the euglycemic hyperinsulinemic clamp method,7
the HOMA-IR index varies widely among populations.8,9 Therefore,
speciﬁc cut-off points to deﬁne insulin resistance in each popula-
tion should be established.
Given the terminological problems of “remission” versus “cure”
and the great heterogeneity among studies in deﬁning remission
criteria for type 2 diabetes mellitus (T2DM), the American Diabetes
Association (ADA) in 2009 deﬁned and agreed the criteria for par-
tial and complete remission that are stricter than those previously
used.10 Given the short time elapsed, scant studies have evaluatedd. All rights reserved.
201 severely obese patients included for bariatric surgery 
Choice of bariatric surgery technique according to clinical criteria
118 patients underwent 
LRYGB
83 patients underwent 
LSG
1 patient receiving 
insulin was excluded
1 patient receiving 
insulin was excluded
2 patients who did not 
complete two years of 
follow-up were excluded
4 patients who did not 
complete two years of 
follow-up were excluded
78 LSG patients 
completed primary 
outcome analysis
115 LRYGB patients 
completed primary 
outcome analysis
Fig. 1. Study ﬂow diagram. LSG, laparoscopic sleeve gastrectomy; LRYGB, laparoscopic Roux-en-Y gastric bypass. No fatal cases were observed.
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patients with these new criteria.5
The primary aim of the present study was to compare insulin
resistance remission rates achieved after LRYGB and LSG, using
population-speciﬁc HOMA-IR cut-off points. Secondary objectives
were to examine T2DM complete remission rates after both tech-
niques according to the new ADA criteria and possible associated
factors and to study changes in HOMA-B during follow-up.
2. Material and methods
2.1. Study protocol
A non-randomized, prospective cohort study was conducted on severely obese
patients undergoing bariatric surgery at the Hospital del Mar, Barcelona. Patients
were aged between 18 and 55 years andmet the 1991 bariatric surgery criteria of the
National Institutes of Health.11 Indication for the type of surgical procedure (LRYGB
or LSG) was based on clinical criteria and the consensus of the Hospital del Mar
Bariatric Surgery Unit. In this respect, LSG was preferred in younger patients, in
those with a BMI of 35e40, as a ﬁrst-step treatment in cases with BMI>50 (although
given the positive LSG outcomes none of these patients had to further undergoTable 1
Baseline characteristics of severely obese patients undergoing LRYGB or LSG with a
minimum of two years of follow-up.
LRYGB (n ¼ 115) LSG (n ¼ 78) p Value
Age (years) 45.0  8.6 45.6  8.7 0.640
Gender (% female) 87.8 76.9 0.037
Weight (Kg) 119.8  15.8 119.3  17.9 0.853
Body mass index (Kg/m2) 45.8  4.3 43.9  5.0 0.006
Waist circumference (cm) 127.6  11.0 125.0  13.5 0.394
Fasting glucose (mg/dl) 110.2  26.7 111.8  27.2 0.691
Insulin (mU/ml) 14.7  8.7 17.8  14.1 0.066
HOMA-IR 4.1  2.8 5.0  4.1 0.075
HOMA-B 140.4  133.1 153.5  128.1 0.506
HbA1c (%) 5.6  0.8 5.7  0.8 0.391
Insulin resistance (%) 56 (48.7) 48 (61.5) 0.054
Type 2 diabetes mellitus (%) 29 (25.2) 20 (25.6) 0.539
LRYG, laparoscopic Roux-en-Y gastric bypass; LSG, laparoscopic sleeve gastrectomy;
HOMA, Homeostatic Model Assesment.
Data presented as mean  standard deviation or percentages. Signiﬁcance at
p < 0.05 was determined using Student’s t-test for continuous variables and chi-
square for categorical variables.LRYGB), and when drug malabsorption was to be avoided. Patients who did not
complete a minimum of 2 year-follow-up were excluded. Because insulinemia is
included in the equation for HOMA index calculation, T2DM patients on insulin
treatment were also excluded.
Sample size was calculated accepting an alpha risk of 0.05 and a beta risk of 0.20
in a two-sided Student’s t-test; 65 subjects were required in each group to detect a
difference 1 in the HOMA-IR index as statistically signiﬁcant. A 3% patient loss rate
during follow-up was expected and a 2 standard deviation was assumed.
In accordance with the study protocol approved by the hospital Ethics Com-
mittee, all patients were evaluated preoperatively and at 3, 6 and 12 months post-
surgery and annually thereafter. Protocol appointments included measurements of
weight, waist and hip circumferences, and laboratory tests including glucose, insulin
and glycosylated hemoglobin (HbA1c) determinations. T2DM pharmacological
treatment was recorded at each visit. All patients signed their informed consent for
the procedure and for the study.
Two hundred and one patients were operated on between January 2006 and
June 2010; of these, 118 underwent LRYGB and 83 LSG. Two diabetic patients (1 of
each group) receiving insulin, and 6 patients (2 of the LRYGB group and 4 of the LSG
group) who did not complete a minimum of 2 years of follow-up were excluded.
Thus, the ﬁnal analysis included 115 patients undergoing LRYGB and 78 LSG (Fig. 1).
2.2. Anthropometric and biochemical measurements
Body mass index (BMI) was calculated as weight in kilograms divided by the
square of height in meters. The percentage of excess weight loss (% EWL) was
calculated based on the excess weight above ideal weight (weight corresponding to
BMI of 25 kg/m2). T2DM diagnosis was deﬁned as two fasting plasma glucose
concentrations above 125 mg/dl or HbA1c 6.5% or treatment with oral hypogly-
cemic agents or insulin.12
Glucose was determined by the oxidase method. HbA1c was quantiﬁed by
chromatography (Biosystem, Barcelona, Spain). Insulin was measured by radioim-
munoassay (Insulin kit, DPC, Los Angeles, USA). HOMA indexes were estimated using
the following formulas6: HOMA-IR ¼ insulin (mU/ml)  fasting glucose (mmol/l)/
22.5 and HOMA-B ¼ 20  insulin (mU/ml)/[ glucose (mmol/l) e 3.5].
In accordance with data from our population, the cut-off for the HOMA-IR index
to deﬁne insulin resistance was a level 3.29.9 Thus, HOMA <3.29 in patients not
using insulin-sensitizing drugs (metformin or glitazones) was established as a cri-
terion of insulin resistance normalization.
T2DM complete remissionwas deﬁned based on the ADA consensus as a plasma
glucose < 100 mg/dl with an HbA1c < 6.0% without drug therapy maintained for at
least one year.10
2.3. Surgical techniques
The LRYGB technique involved a 150-cm antecolic and antegastric Roux limb
with 25-mm circular pouch-jejunostomy, with the exclusion of 50 cm of the prox-
imal jejunum. In LSG, the longitudinal resection of the stomach from the angle of His
to approximately 5 cm proximal to the pylorus was performed using a 36 French
Fig. 2. Changes in percentage of excess weight loss during follow-up after the bariatric
surgical procedure. LRYGB, laparoscopic Roux-en-Y gastric bypass; LSG, laparoscopic
sleeve gastrectomy. Data are expressed as means. Signiﬁcance at p < 0.05 was deter-
mined using Student’s t-test.
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same team of surgeons.
2.4. Statistical analysis
Datawere expressed as mean standard deviation for continuous variables and
as percentages and frequencies for categorical variables. Student’s t-test was per-
formed to assess differences between two means. Chi-square or Fisher exact tests
were used to evaluate the degree of association of categorical variables. Logistic
regression analysis was applied to assess the effects of multiple factors on the T2DM
complete remission rate at two years post-bariatric surgery. A p value <0.05 was
considered statistically signiﬁcant. Statistical analysis was made with SPSS (version
14.0 for Windows; SPSS, Chicago, IL).
3. Results
All 193 patients of the study were Caucasian, with a mean age of
45.2 8.7 years, baseline BMI of 45.0 4.7 kg/m2 andmean follow-
up of 2.9  0.9 years. Baseline characteristics of LRYGB and LSG
patients are listed in Table 1. Patients in the LRYGB group differed
from the LSG group in a higher proportion of women and BMI.
Progressive weight loss, more marked during the ﬁrst 3 months
in the LSG group, was observed in both groups during the ﬁrst year
of follow-up. Thereafter, weight loss remained stable and without
differences between groups (Fig. 2).
At baseline, 56 (48.7%) patients of the LRYGB group and 48
(61.5%) of the LSG had insulin resistance. Three months after sur-
gery, HOMA-IR had decreased dramatically in both groups (Fig. 3A),Fig. 3. Changes in HOMA during follow-up after the bariatric surgical procedure. A: Change
IR: Model to deﬁne insulin resistance, HOMA-B: Model to deﬁne beta-cell function; LRYGB,
expressed as means (standard deviation). Signiﬁcance at p < 0.05 was determined using Stwith a remission rate of 91.1% in the LRYGB patients and 91.7% in the
LSG, p ¼ 0.914. Insulin resistance remission rate achieved after 2
years of follow-up was 92.9% in LRYB group and 87.5% in LSG
(p ¼ 0.355). The HOMA-B index progressively decreased in both
groups during follow-up; however, it was signiﬁcantly higher in the
LSG group at the second and third year post-bariatric surgery
(Fig. 3B).
No differences were observed in baseline characteristics of
T2DM patients between groups (Table 2). According to the
applied bariatric surgery technique, no differences were found in
the T2DM complete remission rate (62.1% for LRYGB and 60% for
LSG, p ¼ 0.992). Factors independently associated with T2DM
complete remission were preoperative diabetes treatment with
diet only, compared with oral drug treatment, and a greater
decrease in HOMA-IR index values three months post-surgery
(Table 3).4. Discussion
The present study showed that two different bariatric surgery
techniques, LRYGB and LSG, are equally effective in achieving in-
sulin resistance normalization using a population-speciﬁc HOMA-
IR cut-off.
Insulin resistance normalizationwas attained with both surgical
techniques in almost all patients as early as 3 months after surgery.
This ﬁnding suggests that weight loss was not the only factor
responsible for the decline in HOMA-IR after bariatric surgery.
Previous studies found that surgical techniques with a mal-
absorptive component like LRYGB produce a greater HOMA-IR
reduction than that obtained after restrictive techniques such as
vertical banded gastroplasty. Furthermore, this reduction occurred
soon after the procedure, when signiﬁcant weight loss had not yet
been achieved.1 These ﬁndings could be explained by changes in
gut hormonal mechanisms, such as increased secretion of incretins
that enhance insulin sensitivity.13,14 In the present study, LSG,
despite being a restrictive technique, produced an early improve-
ment in insulin sensitivity of a similar magnitude to that achieved
with LRYGB. A possible explanation for this ﬁnding could be related
to the characteristics of the LSG technique. LSG includes a gastric
fundus resection, unlike other restrictive techniques, that causes a
decrease in ghrelin concentration, a hormone that produces insulin
resistance.15e17
In the present study, all patients met the criteria for partial
remission and approximately 60% for complete T2DM remission
after a 2 year-follow-up. In other studies comparing LRYGB and LSG,s in HOMA-IR; B: Changes in HOMA-B. HOMA, homeostatic model assessment; HOMA-
laparoscopic Roux-en-Y gastric bypass; LSG, laparoscopic sleeve gastrectomy. Data are
udent’s t-test.
Table 2
Baseline characteristics of severely obese patients with type 2 diabetes mellitus
undergoing LRYG or LSG with a minimum of two years of follow-up.
LRYGB (n ¼ 29) LSG (n ¼ 20) p Value
Age (years) 49.2  6.2 50.6  7.4 0.488
Gender (% female) 79.3 75.0 0.492
Body mass index (Kg/m2) 45.7  4.6 45.6  5.8 0.954
Treatment
Diet alone (%) 16 (55.2) 7 (35) 0.164
Oral hypoglycemic drugs (%) 13 (44.8) 13 (65)
Duration of diabetes (years) 1.3  2.4 1.5  2.5 0.746
Fasting glucose (mg/dl) 143.1  31.0 150.0  25.9 0.415
HbA1c (%) 6.5  0.8 6.9  0.7 0.113
HOMA-IR 6.1  3.3 7.6  4.8 0.212
HOMA-B 123.0  207.6 91.3  81.9 0.553
HbA1c, glycosylated hemoglobin; HOMA, Homeostatic Model Assesment.
Data presented as mean  standard deviation or percentages. Signiﬁcance at
p < 0.05 was determined using Student’s t test for continuous variables and Chi-
square for categorical variables.
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techniques.18e24 The lower T2DM remission rate found in the pre-
sent study could be explained by at least two facts. First, in previous
studies there was a wide heterogeneity in the criteria used for
diabetes remission. In some studies, remission criteria were non-
speciﬁed,19,20,22 others only included diabetes medication with-
drawal,23,24 while others used HbA1c <6.5% and fasting glucose
<125mg/dl oncemedication had beenwithdrawn.18,21 And second,
in addition to stricter biochemical criteria for T2DM remission
(fasting glucose < 100 mg/dl and HbA1c < 6.0%), the new ADA
criteria require these biochemical parameters to be maintained for
at least one year.10
In obese patients with short T2DM duration, such as those in
our study population, insulin resistance predominates over
beta-cell dysfunction.25 Therefore, in these patients, enhancement
of insulin sensitivity is a key factor for glucose metabolism
improvement. This is consistent with the ﬁnding that HOMA-IR
reduction 3 months post-surgery was a predictor of T2DM com-
plete remission two years after the procedure. Moreover, the short
duration of diabetes of the subjects included in this study may
explain the lack of association of diabetes remision with other
factors previously described such as waist circumference and
T2DM duration.26,27
The HOMA-B index is a marker of pancreatic beta-cell function.
In a healthy subject with a normal BMI and no family history of
diabetes mellitus, the HOMA-B index is expected to be close to 100,
indicating optimal beta-cell function (100%). Subjects in the present
study had a mean baseline level above 100 that progressively
decreased during follow-up. These results suggest that, preopera-
tively, beta cells in these patients had a compensatory hyperfunc-
tion and, after bariatric surgery, insulin resistance remission caused
a decline in this compensatory insulin secretion, reﬂected in aTable 3
Factors related to complete remission of type 2 diabetes mellitus two years after
surgery. Odds ratio (OR) obtained by logistic regression analysis.
OR 95% conﬁdence
interval
p Value
Age 0.91 0.78e1.06 0.217
Diet therapy alone 9.69 1.36e69.10 0.023
LRYGB 0.71 0.11e4.77 0.722
Decrease in HOMA-IR
units at 3 months
1.31 1.01e1.70 0.045
% EWL at 3 months 1.07 0.99e1.14 0.60
LRYGB, laparoscopic Roux-en-Y gastric bypass; HOMA, Homeostatic Model
Assessment; % EWL, percentage excess weight loss.reduction in the HOMA-B index. On the other hand, surgical tech-
niques with a malabsorptive component cause an increase in hor-
mones with an incretin effect. These hormones raise insulin
secretion, but only in the postprandial period. Therefore, the
HOMA-B index, which estimates beta-cell function in the fasting
state, would not be the optimal method of evaluating postprandial
insulin secretion improvement in these patients.28
Thepresent studywasnotwithout limitations. First, patientswere
not randomly assigned to either of the bariatric surgery techniques
and therefore the baseline characteristics of patients included in each
groupwere not comparable. Second, diabetic patients included in the
present study had a short disease duration, the majority did not
requirepharmacological treatment and thoseon insulin therapywere
excluded. Therefore, the results found cannot be generalized to the
whole diabetic population. Finally, insulin resistance was assessed
using the HOMA-IR index; however, a more accurate method for
quantifying insulin resistance, the euglycemic hyperinsulinemic
clamp, was not used since it is invasive and time-consuming.
5. Conclusion
In conclusion, LRYGB and LSG are equally effective in achieving
insulin resistance normalization in almost all patients. Further-
more, both techniques achieved similar T2DM complete remission
rates and HOMA-IR reduction at 3 months after surgery was the
main predictor. The HOMA-B index should be carefully interpreted
in these patients.
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